| Document |
Document Title |
|
WO/2003/095526A1 |
A sulfurized phenolic resin containing, between phenolic carbon atoms, an organic group represented by the following formula (1): −R1−S−R2−S−R1− (1) (wherein R1 represents a C2−6 hydrocarbon group and R2 represents a C1−1...
|
|
WO/2003/095420A1 |
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...
|
|
WO/2003/093302A2 |
A process is provided for the solid-phase synthesis of a peptide amide which comprises attaching a &agr -nitrogen protected C&agr -carboxamide amino acid to a solid support by its side chain, removing the &agr -nitrogen protecting group,...
|
|
WO2002044124A9 |
A three-dimensional molecular array on one of a conductor and semiconductor surface is disclosed. The array comprises at least one columnar stack comprising a plurality of substituted aromatic rings, wherein the aromatic rings of each co...
|
|
WO/2003/093301A2 |
A process for the solid-phase synthesis of a peptide is provided which comprises attaching an &agr -nitrogen protected &agr -carboxy protected amino acid to a solid support via its side chain, removing the &agr -nitrogen protecting group...
|
|
WO/2003/093226A1 |
A process for synthesizing pharmaceutically active disulfides, particularly Dimesna and certain derivatives thereof. The process includes reacting an alkylene salt with a sulfurating reagent, then alkalizing the intermediate and flowing ...
|
|
WO/2003/093250A2 |
The invention provides compounds of Formula I: (1) these compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases...
|
|
WO/2003/093224A1 |
Compounds of the formula (R5)m-(R6A)-2-(R4)-1-[N= C(R1)N(R2)(R3)]benzene and their agriculturally suitable salts, are disclosed which are useful as fungicides, wherein R1 is H, OH, SH, SO3H, CN, -OR7 or -SR7; C1-C10 alkyl, C2-C10 alkenyl...
|
|
WO/2003/091262A1 |
New ligands, compositions, metal-ligand complexes and arrays with bridged bis-aromatic ligands are disclosed that catalyze the polymerization of monomers into polymers. These catalysts with metal centers have high performance characteris...
|
|
WO/2003/087034A1 |
The invention relates to 3-aminophenol derivatives of formula (I) or to their physiologically compatible, water-soluble salts, wherein R1 is identical to a radical of formula (II) or to a radical of formula (III), and to dyes that contai...
|
|
WO/2003/087045A1 |
Novel compounds of Formula (I) which modulate MCH activity are disclosed, in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH2 group, Q together with the c...
|
|
WO/2003/087026A1 |
Compounds of the general formula (I) are valuable therapeutics for the treatment of cancer and cancer related diseases.
|
|
WO/2003/086282A2 |
The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one...
|
|
WO/2003/087047A1 |
The present invention provides a novel metal chelate composition and its macromolecule complex. The invention also provides a preparation method of the metal chelate composition and method of using the metal chelate composition in purify...
|
|
WO/2003/084938A2 |
AbstractThe present invention relates to novel pyrimidone derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their phar...
|
|
WO/2003/084936A2 |
The present invention relates to novel amino substituted pyrimidinone derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates...
|
|
WO/2003/084935A2 |
The present invention relates to novel diaryl pyrimidinedione derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their ...
|
|
WO/2003/084937A2 |
The present invention relates to novel pyrimidinedione derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmac...
|
|
WO/2003/084917A1 |
Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: (I) wherein A, R1 , R2 , Rx , R8 , R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions c...
|
|
WO/2003/084924A2 |
Disclosed are compounds comprising both disulfide functionality and electron donor functionality or alkoxy siloxane functionality, and curable compositions comprising compounds comprising both disulfide functionality and electron donor f...
|
|
WO/2003/084997A1 |
Aspects of the present invention include probes, methods, systems that have stand alone utility and may comprise features of a drug discovery system or method. The present invention also includes pharmaceutical compositions. In more deta...
|
|
WO/2003/084916A2 |
This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods o...
|
|
WO/2003/084982A2 |
The present invention relates to improved covalent coupling of two or more entities such as biomolecules, polymer compositions, organic/inorganic molecules/materials, and the like, including their combinations, through one or more novel ...
|
|
WO/2003/084912A1 |
Benzoylcyclohexanedione derivatives of formula (I) and use thereof as herbicides are disclosed. In said general formula (I) R1a, R1b, R1c, R2, R3, R4 and R5 = various groups, X1 = a bridging atom, X2 = a hydrocarbon chain and X3 = a chal...
|
|
WO/2003/082205A2 |
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...
|
|
WO/2003/082787A1 |
Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate,or salt thereof; pharmaceutical compositions containing such compounds,...
|
|
WO/2003/082813A2 |
A compound comprising a cyclopentanone, cyclopentenone, cyclohexanone or cyclohexenone group, wherein a first ring carbon atom carries an -SR substituent, R is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl, aralke...
|
|
WO/2003/082260A2 |
A method of preventing or treating diseases caused by Mycobacterium, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.
|
|
WO/2003/079984A2 |
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...
|
|
WO/2003/080631A2 |
Compounds of the following formula (I), for example: (1), wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using th...
|
|
WO/2003/080042A1 |
A medicinal composition which contains a compound represented by the general formula (I): (I) wherein R1 is hydroxy, etc.; R2 is optionally substituted lower alkyl, etc.; R3 is hydrogen, etc.; R4 is optionally substituted allylene, etc.;...
|
|
WO/2003/080041A1 |
It is intended to provide remedies or preventives for arthritis deformans and/or rheumatoid arthritis comprising as the active ingredient a compound represented by the following formula (I), its optical isomers, prodrugs thereof or pharm...
|
|
WO/2003/080568A2 |
Probucol derivatives and pharmaceutical compositions containing the same to be employed in treatment or prophylaxis of diseases.
|
|
WO/2003/078393A2 |
This invention relates to novel fluorinated phenyl thiphenyl (also named diarylsulfide) derivatives and their use in Positron Emission Tomagraphy (PET) imaging of Serotonin Transporters (SERTS). The present invention also provides diagno...
|
|
WO/2003/077847A2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
WO/2003/078390A1 |
A novel phenolic compound; and a recording material containing the compound and having excellent storage stability. The phenolic compound is represented by the formula (I): (I) wherein m is an integer of 0 to 2; R1 and R2 each independen...
|
|
WO2003029199A9 |
Novel benzene derivatives represented by the general formula (||), which exhibit vanilloid receptor agonism and are useful as preventive and therapeutic drugs for pollakisuria and urinary incontinence, analgesic, or the like: (||) wherei...
|
|
WO/2003/078382A1 |
N-Biphenylamides represented by the general formula (1) have excellent control activities against plant diseases: (1) wherein R1, R2, R3, R4, and R5 are each independently hydrogen, halogeno, or the like; R6 is C1-6 alkyl or the like; R7...
|
|
WO2002062750A9 |
There are disclosed compounds of the formula (I) a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disc...
|
|
WO/2003/076397A1 |
The present invention relates to a compound formula [I] wherein R1 and R5 are each independently hydrogen, halogen, lower alkyl, etc., R2 is hydrogen or an amino protective group, x is bond,-o-o,-O-CH2-, etc., y is in which Z is bond, -0...
|
|
WO/2003/076450A1 |
Late transition metal complexes of certain ligands which contain phosphinidine and/or imine groups are useful as components of polymerization catalysts for olefins. Useful metals in the complexes include Ni, Pd, Fe and Co. Oligomers and/...
|
|
WO/2003/075857A2 |
Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.
|
|
WO/2003/075907A2 |
The present invention concerns a compound having the formula (I) a N-oxide form, a stereochemical isomer, racemic mixture, salt prodrug, ester or metabolite thereof. It further relates to processes for their preparation as well as pharma...
|
|
WO/2003/076406A1 |
Compounds of formula (I) in which each of the phenyl rings represented is optionally substituted one or more times; n represents an integer selected from 0, 1, 2, 3, 4 and 5; W represents -CO-or -SO2-; Z represents H; alkyl; aryl; or ary...
|
|
WO/2003/075853A2 |
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ tra...
|
|
WO2002002684A9 |
The invention relates to stabilisers containing at least two phenolic groups which are connected by a polyol, with a number average molecular weight of 75xF g/mol to 250xF g/mol, preferably 100xF g/mol to 200xF g/mol, in particular 100xF...
|
|
WO/2003/074476A1 |
An arylamidine derivative represented by the general formula (1) (wherein X means optionally substituted lower alkylene or alkenylene; G1 means oxygen, sulfur, or imino; G2 means carbon or nitrogen; Ra means at least one member selected ...
|
|
WO/2003/074038A1 |
METHODS FOR TREATING DISEASES RELATED TO INTRAOCULAR PRESSUREABSTRACT OF THE DISCLOSUREThis invention relates to the use of compounds able to decrease potassium ion flow through intermediate conductance calcium activated potassium channe...
|
|
WO/2003/072537A2 |
Compounds of formula (I), or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the ...
|
|
WO/2003/072614A2 |
A photopolymerization initiator composition containing a thiol compound having a mercapto group-containing group that has at least one substituent on the carbon atoms on carbon atom(s) at the &agr - and/or β- position with respect to th...
|
